Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
P/B ratio for Tango Therapeutics, Inc. (TNGX)
P/B ratio as of 2023: 3.70
According to Tango Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.70. At the end of 2022 the company had a P/B ratio of 2.55.
P/B ratio history for Tango Therapeutics, Inc. from 2019 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 3.70 |
| 2022 | 2.55 |
| 2021 | 1.97 |
| 2020 | 9.46 |
| 2019 | 11.63 |